FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients
Srđan Verstovšek(Unknown), Jean‐Jacques Kiladjian(Délégation Paris 5), Andreas Reiter(Heidelberg University), Hui‐Ling Zhen(Incyte (United States)), Jay Patel(University of Utah), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Jason Gotlib(Stanford University), Philomena Colucci(Incyte (United States)), William Shomali(Stanford Medicine), Natália Oliveira(Incyte (United States)), Tracy I. George(University of Utah)
Cited by 14
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k